Literature DB >> 33968439

New insights in the pathology of peritoneal surface malignancy.

Norman John Carr1.   

Abstract

Pathology is central to the management of peritoneal surface malignancy. This article highlights some recent advances that have had an impact on patient management or could do so in the near future. Malignant peritoneal mesothelioma, particularly the epithelioid subtype, is amenable to radical therapy in selected cases, and factors such as ki67 proliferation index, expression of BAP1 and mutation in CDKN2A show promise as prognostic indicators. Our understanding of multicystic mesothelioma has improved in recent years; it is a true neoplasm for which surgery may be indicated. Serous carcinomas involving the peritoneum are now known to originate from tubal epithelium. They are of two distinct types, high grade and low grade, which are now recognized as different neoplasms with distinctive features, oncogenesis and behavior. Pseudomyxoma peritonei (PMP) is an unusual condition that usually arises from an appendiceal mucinous neoplasm. Recent consensus in the classification and nomenclature of these lesions is discussed, including the distinction between low grade and high grade appendiceal mucinous neoplasms (HAMN), and the diagnostic criteria for appendiceal adenocarcinoma. PMP is divided into four prognostic groups: acellular mucin, low grade mucinous carcinoma peritonei, high grade mucinous carcinoma peritonei, and high grade mucinous carcinoma peritonei with signet ring cells. The pseudomyxoma microbiome is a promising area for clinical intervention but has been the subject of little research activity. Goblet cell adenocarcinoma (previously known as 'goblet cell carcinoid') is a distinctive type of appendiceal adenocarcinoma. Its behavior correlates with histologic features, but no general consensus for classification has been reached. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Appendiceal neoplasms; mesothelioma; peritoneal neoplasms; pseudomyxoma peritonei (PMP); serous carcinoma

Year:  2021        PMID: 33968439      PMCID: PMC8100698          DOI: 10.21037/jgo-2020-01

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  121 in total

1.  Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients.

Authors:  Sandy Liu; Paul Staats; Michael Lee; H Richard Alexander; Allen P Burke
Journal:  Pathology       Date:  2014-12       Impact factor: 5.306

2.  EGFR, KRAS, BRAF-mutations and microsatellite instability are absent in goblet cell carcinoids of the appendix.

Authors:  Arno Dimmler; Helene Geddert; Gerhard Faller
Journal:  Pathol Res Pract       Date:  2014-01-31       Impact factor: 3.250

3.  Outcomes of Low-Grade Appendiceal Mucinous Neoplasms with Remote Acellular Mucinous Peritoneal Deposits.

Authors:  Campbell S Roxburgh; Yaniv M Fenig; Andrea Cercek; Jinru Shia; Rachel M Rassam; Philip B Paty; Garrett M Nash
Journal:  Ann Surg Oncol       Date:  2018-11-12       Impact factor: 5.344

4.  Treatment patterns and outcomes in goblet cell carcinoid tumors of the appendix.

Authors:  Adam C Fields; Pamela Lu; Andrea Enzinger; Joel Goldberg; Jennifer Irani; Ronald Bleday; Garrett Nash; Nelya Melnitchouk
Journal:  J Surg Oncol       Date:  2019-10-08       Impact factor: 3.454

5.  Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.

Authors:  Cristina Semino-Mora; Hui Liu; Thomas McAvoy; Carol Nieroda; Kimberley Studeman; Armando Sardi; Andre Dubois
Journal:  Ann Surg Oncol       Date:  2008-02-26       Impact factor: 5.344

6.  Surgical and chemotherapy treatment outcomes of goblet cell carcinoid: a tertiary cancer center experience.

Authors:  Tuan H Pham; Bruce Wolff; Susan C Abraham; Ernesto Drelichman
Journal:  Ann Surg Oncol       Date:  2006-01-30       Impact factor: 5.344

7.  Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort.

Authors:  Waqas Amin; Faina Linkov; Douglas P Landsittel; Jonathan C Silverstein; Michael J Becich
Journal:  F1000Res       Date:  2018-08-03

8.  Clinical and surgical outcomes of patients with peritoneal mesothelioma discussed at a monthly national multidisciplinary team video-conference meeting.

Authors:  A Brandl; S Westbrook; S Nunn; E Arbuthnot-Smith; J Mulsow; H Youssef; N Carr; A Tzivanakis; S Dayal; F Mohamed; B J Moran; T Cecil
Journal:  BJS Open       Date:  2020-01-30

Review 9.  Peritoneal cystic mesothelioma: a case series.

Authors:  Kaiumarz Sethna; Faheez Mohamed; Pierre Marchettini; Dominique Elias; Paul H Sugarbaker
Journal:  Tumori       Date:  2003 Jan-Feb

10.  A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma.

Authors:  Jun Lai; Zhan Zhou; Xiao-Jing Tang; Zhi-Bin Gao; Jie Zhou; Shu-Qing Chen
Journal:  Int J Mol Sci       Date:  2016-05-14       Impact factor: 5.923

View more
  3 in total

Review 1.  Postoperative bleeding and venous thromboembolism in colorectal cancer patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis.

Authors:  Mikkel Lundbech; Andreas Engel Krag; Lene Hjerrild Iversen; Anne-Mette Hvas
Journal:  Int J Colorectal Dis       Date:  2021-10-09       Impact factor: 2.571

2.  Fear of cancer recurrence in peritoneal malignancy patients following complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): an observational study protocol.

Authors:  Rayan Taher; Sophia Stanford; Norman Carr; Nancy Vanderpuye; Kandiah Chandrakumaran
Journal:  BMJ Open       Date:  2022-02-14       Impact factor: 2.692

3.  Malignant peritoneal mesothelioma literature review: past, present, and future.

Authors:  Stephanie N Gregory; A Leila Sarvestani; Andrew M Blakely
Journal:  Dig Med Res       Date:  2022-06-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.